CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations

Clinical Pharmacology and Therapeutics

Volumn 95, Issue 2, 2014, Pages 216-227

  Province, Michael A ^a,aj   Goetz, Matthew P ^o   Brauch, Hiltrud ^r   Flockhart, David A ^y   Hebert, Joan M ^b   Whaley, Ryan ^b,ai   Suman, Vera J ^o,ah   Schroth, Werner ^r   Winter, Stefan ^r   Zembutsu, Hitoshi ⁱ   Mushiroda, Taisei ^g,i   Newman, William G ^h   Lee, M T M ^g   Ambrosone, Christine B ^j   Beckmann, Matthias W ^s   Choi, Ji Yeob ^b   Dieudonné, Anne Sophie ⁿ   Fasching, Peter A ^s   Ferraldeschi, Roberta ^h   Gong, Li ^b   Haschke Becher, Elisabeth ^f   Howell, Anthony ^h   Jordan, Lee B ^aa,af   Hamann, Ute ^ae   Kiyotani, Kazuma ⁱ   Krippl, P ^q   Lambrechts, Diether ^l   Latif, Ayse ^h   Langsenlehner, U ^q   Lorizio, Wendy ^r   Neven, Patrick ⁿ   Nguyen, Anne T ^y   Park, Byeong Woo ^t   Purdie, Colin A ^aa,af   Quinlan, Philip ^af   Renner, W ^q   Schmidt, Marcus ^ag   Schwab, Matthias ^r   Shin, Jae Gook ^b   Stingl, Julia C ^d   Wegman, Pia ^f   Wingren, S ^aa   Wu, Alan H B ^r   Ziv, Elad ^r   Zirpoli, G ⁱ   Thompson, Alastair M ^h   Jordan, V C ^ac   Nakamura, Y ^f   Altman, Russ B ^ai   Ames, M M ^b   Weinshilboum, Richard M ^o   Eichelbaum, Michel ^r   Ingle, James N ^o   Klein, Teri E ^b,ai   Boländer, Julia ^ae   Ulmer, Hans Ulrich ^ae   Fischer Bosch, Margarete ^c   Fritz, Peter ^r   Simon, Wolfgang ^r   Bryan, Y ⁱ   Strick, Reiner ^s   Koelbl, Heinz ^ag   Ambrosone, Christine A ^h   H, Elad Ziv ^r   more..

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d INDIANA UNIVERSITY   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF TOKYO   (Japan)

^g RIKEN   (Japan)

^h UNIVERSITY OF MANCHESTER   (United Kingdom)

ⁱ ROSWELL PARK CANCER INSTITUTE   (United States)

^j UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^k Seoul National University   (South Korea)

^l UNIVERSITY OF LEUVEN   (Belgium)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ PARACELSUS MEDICAL UNIVERSITY   (Austria)

^o UNIVERSITY OF DUNDEE   (United Kingdom)

^p GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^q MEDICAL UNIVERSITY OF GRAZ   (Austria)

^r UNIVERSITY OF CALIFORNIA   (United States)

^s UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^t Yonsei University College of Medicine   (South Korea)

^u Dundee Cancer Centre   (United Kingdom)

^v JOHANNES GUTENBERG UNIVERSITY   (Germany)

^w UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^x Inje University College of Medicine   (South Korea)

^y Inje University College of Medicine   (South Korea)

^z UNIVERSITY OF BONN   (Germany)

^aa ÖREBRO UNIVERSITY   (Sweden)

^ab UNIVERSITY OF CALIFORNIA   (United States)

^ac GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^ad Stanford University   (United States)

^ae STÄDTISCHES KLINIKUM KARLSRUHE   (Germany)

^af UNIVERSITY OF DUNDEE   (United Kingdom)

^ag IKP Stuttgart   (Germany)

^ah Inje University   (South Korea)

^ai STANFORD UNIVERSITY   (United States)

^aj WASHINGTON UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; TAMOXIFEN;

ARTICLE; DISEASE FREE SURVIVAL; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FOLLOW UP; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MENOPAUSE; META ANALYSIS; PRIORITY JOURNAL; TREATMENT DURATION;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; MENOPAUSE; MIDDLE AGED; PHARMACOGENETICS; SURVIVAL ANALYSIS; TAMOXIFEN; TREATMENT OUTCOME;

EID: 84893732936     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.186     Document Type: Article

References (26)

1. Jordan, V.C. Tamoxifen: A most unlikely pioneering medicine. Nat. Rev. Drug Discov. 2, 205-213 (2003).
2. Davies, C. et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials. Lancet 378, 771-784 (2011).
3. Johnson, M.D. et al. Pharmacological characterization of 4-hydroxy-Ndesmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res. Treat. 85, 151-159 (2004).
4. Stearns, V. et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl. Cancer Inst. 95, 1758-1764 (2003).
5. Goetz, M.P., Berry, D.A. & Klein, T.E. 31136 Findings from the International Tamoxifen Pharmacogenomics Consortium. Proceedings of the San Antonio Breast Cancer Symposium, San Antonio, Texas, 9-13 December 2009. Abstract 33.
6. Mürdter, T.E. et al.; German Tamoxifen and AI Clinicians Group. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin. Pharmacol. Ther. 89, 708-717 (2011).
7. Irvin, W.J. Jr et al. Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: A multicenter study. J. Clin. Oncol. 29, 3232-3239 (2011).
8. Rae, J.M. et al.; COBRA investigators. Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. Pharmacogenomics J. 9, 258-264 (2009).
9. Schroth, W. et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302, 1429-1436 (2009).
10. Goetz, M.P. et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol. 23, 9312-9318 (2005).
11. Rae, J.M. et al.; ATAC trialists. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J. Natl. Cancer Inst. 104, 452-460 (2012).
12. Regan, M.M. et al.; Breast International Group (BIG) 1-98 Collaborative Group. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The breast international group 1-98 trial. J. Natl. Cancer Inst. 104, 441-451 (2012).
13. Brauch, H. et al. Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. J. Clin. Oncol. 31, 176-180 (2013).
14. Nakamura, Y., Ratain, M.J., Cox, N.J., McLeod, H.L., Kroetz, D.L. & Flockhart, D.A. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The Breast International Group 1-98 trial. J. Natl. Cancer Inst. 104, 1264; author reply 1266-1268 (2012).
15. Stanton, V. Jr. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The Breast International Group 1-98 trial. J. Natl. Cancer Inst. 104, 1265-6; author reply 1266-8 (2012).
16. Goldberg, P. Experts claim errors in breast cancer study, demand retraction of practice-changing paper. The Cancer Letter 38, 1-11 (2012).
17. Goetz, M.P. et al. CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) Clin. Cancer Res. 19, 500-507 (2013).
18. Schroth, W. et al. CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: Expanded polymorphism coverage improves risk stratification. Clin. Cancer Res. 16, 4468-4477 (2010).
19. Zanger, U.M., Turpeinen, M., Klein, K. & Schwab, M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal. Bioanal. Chem. 392, 1093-1108 (2008).
20. Castells, A., Gusella, J.F., Ramesh, V. & Rustgi, A.K. A region of deletion on chromosome 22q13 is common to human breast and colorectal cancers. Cancer Res. 60, 2836-2839 (2000).
21. Hirano, A. et al. Allelic losses of loci at 3p25.1, 8p22, 13q12, 17p13.3, and 22q13 correlate with postoperative recurrence in breast cancer. Clin. Cancer Res. 7, 876-882 (2001).
22. Loo, L.W. et al. Differential patterns of allelic loss in estrogen receptor-positive infiltrating lobular and ductal breast cancer. Genes. Chromosomes Cancer 47, 1049-1066 (2008).
23. Thompson, A.M. et al. Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res. Treat. 125, 279-287 (2011).
24. French, B. et al.; COAG (Clarification of Optimal Anticoagulation through Genetics) Investigators. Statistical design of personalized medicine interventions: The Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Trials 11, 108 (2010).
25. Hudis, C.A. et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: The STEEP system. J. Clin. Oncol. 25, 2127-2132 (2007).
26. DerSimonian, R. & Laird, N. Meta-analysis in clinical trials. Control. Clin. Trials 7, 177-188 (1986).